Co-founded in 2017 by two pioneers in genome editing technology, Qihan Biotech has world-leading capabilities in multiplexable genome editing as well as vast experience in Immune shielding. We apply these tools in both human stem cells and animal germline cells to deliver novel immune-privileged cell and organ therapies. A world in which cell and organ therapies are universally available to patients. Use multiplexable genome e...
Co-founded in 2017 by two pioneers in genome editing technology, Qihan Biotech has world-leading capabilities in multiplexable genome editing as well as vast experience in Immune shielding. We apply these tools in both human stem cells and animal germline cells to deliver novel immune-privileged cell and organ therapies. A world in which cell and organ therapies are universally available to patients. Use multiplexable genome editing in combination with extensive knowledge in transplantation immunology to create immunologically privileged allogenic cells and xenogeneic organs for use as therapies to treat cancer. ect.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.